News Release

AMGEN ASTELLAS BIOPHARMA AND ASTELLAS INTRODUCE REPATHA® (EVOLOCUMAB) FOR THE TREATMENT OF HIGH CHOLESTEROL

FIRST PCSK9 INHIBITOR IN JAPAN, PROVIDING A NEW TREATMENT OPTION FOR CERTAIN PATIENTS WHO HAVE HIGH RISK IN CARDIOVASCULAR EVENTS AND DO NOT ADEQUATELY RESPOND TO STATINS

TOKYO (April 21, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Eiichi Takahashi, "Amgen Astellas") and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO: Yoshihiko Hatanaka, "Astellas") announced that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha® SC Injection (generic name: Evolocumab (Genetically Recombination) Injection) 140 mg Syringe has become available in the Japanese market today.

Repatha® is indicated for the treatment of patients with familial hypercholesterolemia (FH) or hypercholesterolemia who have high risk of cardiovascular events and do not adequately respond to HMG-CoA reductase inhibitors (statins).

Repatha® is a human monoclonal antibody that inhibits PCSK9.[1] Repatha® binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha® increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.[2]

Yukiya Suzuki, the Head of Sales and Marketing of Amgen Astellas said, "Amgen Astellas is a Tokyo-based joint venture between Amgen, a biotechnology company with a history of more than 35 years of providing innovative medicines worldwide, and Astellas Pharma Inc., a company with a deep understanding and expertise in serving the medical needs of Japanese patients and physicians. Amgen Astellas began operations in 2013, and today we are pleased to begin providing Repatha®, the first product of Amgen Astellas and Japan's first PCSK9 inhibitor. We are committed to serving the medical needs of the country and are excited about the potential of Repatha® to help improve the treatment of patients with high cholesterol who have high risk in cardiovascular events and do not adequately respond to statins."

Yukihiko Sato, Senior Vice President, Sales & Marketing Japan of Astellas said, "We expect Repatha® as a new therapeutic option will contribute further to the patients with cardiovascular disease."

Amgen Astellas and Astellas will co-promote Repatha®.

Product outline of "Repatha® SC Injection 140mg Syringe" is as follows.

Brand name:	Repatha® SC Injection 140mg Syringe
Generic name:	Evolocumab （Genetically Recombination）
Indication:	Familial Hypercholesterolemia, Hypercholesterolemia Only when patients who have high risk in cardiovascular events and do not adequately respond to HMG-CoA Reductase Inhibitors
Precautions Related to Indications:	（1） Prior to evolocumab therapy, patients should have a confirmed diagnosis of familial hypercholesterolemia or hypercholesterolemia by going through assessment. （2） When applying evolocumab to patients with non-familial hypercholesterolemia, it should be carefully considered for patients who have high risk of cardiovascular events based on risk factors e.g. comorbid conditions including coronary artery disease, non-cardiogenic stroke, peripheral arterial disease, diabetes and chronic renal disease or medical history.
Dosage regimen:	Heterozygous Familial Hypercholesterolemia and Hypercholesterolemia：In general, for adults, evolocumab (genetically recombination) of 140mg is administrated every 2 weeks or evolocumab of 420mg is administrated every 4 weeks subcutaneously Homozygous Familial Hypercholesterolemia：In general, for adults, evolocumab (genetically recombination) of 420mg is administrated every 4 weeks subcutaneously. Evolocumab of 420mg every 2 weeks can be administered when the efficacy is not adequate. If evolocumab is administered as adjunctive therapy for patients with LDL apheresis, as starting dose, evolocumab of 420mg every 2 weeks can be administered subcutaneously
Precautions Related to Dosage and Administration:	Evolocumab should be administered as an adjunct to HMG-CoA reductase inhibitor therapy [Efficacy and safety of evolocumab monotherapy in Japanese patients not confirmed.]
Price	Repatha® SC Injection 140mg Syringe： 22,948yen
Drug Price Listing Date	April 20, 2016
Launch Date	April 21, 2016

* For more information, please see the latest Japan Prescribing Information.
* The official guidance of point to consideration regarding Repatha® under the coverage of National Health Insurance is issued by Medical Affairs Division of Ministry of Health, Labour and Welfare.



About Amgen Astellas BioPharma K.K.
Amgen Astellas BioPharma K.K. is a Japanese company that began operations on October 1, 2013, to provide breakthrough-science-based medicines to help address unmet medical needs of patients in Japan. The company is a joint venture between Amgen, one of the world's leading independent biotechnology companies, and Astellas Pharma Inc., a leading Tokyo-based R&D oriented global pharmaceutical company. The joint venture will become a wholly-owned Amgen affiliate as soon as 2020. Amgen Astellas leverages the capabilities of both companies – Amgen's science and pipeline candidates coupled with Astellas' deep knowledge of Japanese patient and physician needs, long-term commercial and regulatory experience, and strong presence as a leading company in Japan – to contribute to the creation of a healthy society.

Amgen Astellas has grown into an organization equipped with comprehensive functions to be fully operational as a marketing authorization holder. The total number of employees today exceeds 300, including its sales organization in 19 regional sales offices located across Japan, under the leadership of three regional sales directors to adequately serve the medical needs of the country.

About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international

trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. We are increasingly dependent on information technology systems, infrastructure and data security. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

###

Media Contact	
Amgen Astellas BioPharma K.K. Corporate Affairs TEL: +81-3-5293-9694 FAX: +81-3-5293-9897 http:// http://www.aabp.co.jp/jp/	Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201 FAX:+81-3-5201-7473 http://www.astellas.com/en/

References

1. Amgen Data on File, Investigator Brochure.
2. Data on File: Study 20120122 Phase III in Japanese study report.